These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33565026)

  • 1. Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine.
    Tsai M; Nery ESM; Kerr L; Khanna R; Komori M; Dennehy EB; Wilbraham D; Winner P
    Clin Pharmacokinet; 2021 Jun; 60(6):819-828. PubMed ID: 33565026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
    Zhou J; Luo G; Xu Y; Yang X; Pan X; Dong Z; Zhong S; Liu H; Ji F; Yu S
    Adv Ther; 2022 Nov; 39(11):5229-5243. PubMed ID: 36114949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
    Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
    Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
    Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
    Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
    Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
    J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
    Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
    Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
    Martin VT; Ahmed Z; Hochstetler HM; Baygani SK; Dong Y; Hauck PM; Khanna R
    Clin Ther; 2021 Jun; 43(6):1066-1078. PubMed ID: 34366152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
    Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
    Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
    Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine.
    Tassorelli C; Bragg S; Krege JH; Doty EG; Ardayfio PA; Ruff D; Dowsett SA; Schwedt T
    J Headache Pain; 2021 Nov; 22(1):132. PubMed ID: 34742230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
    CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.
    Komori M; Ozeki A; Tanji Y; Kamiki E; Krege JH; Li LQ; Suzuki S; Shibata M; Takeshima T
    J Headache Pain; 2024 Mar; 25(1):43. PubMed ID: 38528476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
    Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
    Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial.
    Takeshima T; Komori M; Tanji Y; Ozeki A; Tatsuoka Y
    Adv Ther; 2022 Nov; 39(11):5274-5288. PubMed ID: 36138260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
    Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
    J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasmiditan in patients with common migraine comorbidities: a
    Clemow DB; Baygani SK; Hauck PM; Hultman CB
    Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
    Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
    BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasmiditan for the acute treatment of migraine.
    DeJulio PA; Perese JK; Schuster NM; Oswald JC
    Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.